General MedicationsORALGeneric

ABACAVIR SULFATE; LAMIVUDINE

Standard Dose

60MG; 30MG

Max Dose

Refer to approved labeling

Primary Use

Review priority: PRIORITY Marketing status: None (Tentative Approval)

Summary

Approval overview ABACAVIR SULFATE; LAMIVUDINE is listed in Drugs@FDA under application 202007 (NDA).

Review priority: PRIORITY Marketing status: None (Tentative Approval) Active ingredient ABACAVIR SULFATE; LAMIVUDINE Form and strength TABLET, FOR SUSPENSION; ORAL - 60MG; 30MG Sponsor CIPLA LIMITED Submission history Latest submission status date: 2011-05-12 00:00:00.

Structured Monograph

Clinical summary

Approval overview ABACAVIR SULFATE; LAMIVUDINE is listed in Drugs@FDA under application 202007 (NDA). Review priority: PRIORITY Marketing status: None (Tentative Approval) Active ingredient ABACAVIR SULFATE; LAMIVUDINE Form and strength TABLET, FOR SUSPENSION; ORAL - 60MG; 30MG Sponsor CIPLA LIMITED Submission history Latest submission status date: 2011-05-12 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: None (Tentative Approval)
• Review priority: PRIORITY

Interaction Notes

No interaction notes stored yet.